Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
novavax
Overview
Novavax, Inc., a publicly traded biotechnology company (Nasdaq: NVAX), specializes in the research, development, and commercialization of innovative vaccines to combat serious infectious diseases. Operating within the biopharmaceutical industry, Novavax distinguishes itself through its proprietary recombinant nanoparticle vaccine technology and Matrix-M adjuvant, which have been instrumental in developing vaccines for COVID-19, influenza, and RSV. With a renewed focus on profitability and sustainable growth after the initial COVID-19 vaccine surge, Novavax aims to establish itself as a significant player in the global vaccine market, targeting both pandemic preparedness and endemic disease prevention.
novavax's headcount breakdown by department
| Department | HeadCount |
|---|---|
Administrative | 27 |
Consulting | 10 |
Service | 1 |
Design | 1 |
Education | 2 |
Novavax's department distribution reflects a biopharmaceutical company heavily invested in research and development, manufacturing operations, and regulatory compliance, which is typical for a vaccine manufacturer. The relatively large 'Research' department (174 employees) signifies a strong commitment to innovation and the discovery of new vaccines and technologies. A substantial 'Operations' department (131 employees) underscores the company's focus on scaling production, ensuring supply chain efficiency, and maintaining quality control, crucial aspects of vaccine manufacturing. The sizable 'Legal' department (52 employees) indicates a strong emphasis on navigating the complex regulatory landscape governing vaccine development, intellectual property protection, and commercialization. A significant 'Technical' department (88 employees) is necessary to support the sophisticated manufacturing processes and advanced technologies inherent in vaccine production. The smaller 'Sales' (26 employees) and 'Marketing' (12 employees) departments, relative to other areas, suggest that Novavax's business model relies significantly on direct sales to governments, global health organizations, and large-scale distributors rather than direct-to-consumer marketing, aligning with vaccine market dynamics. Furthermore, the size of the 'Medical' department (46 employees) is critical for managing clinical trials, post-market surveillance, and engaging with healthcare professionals, essential for gaining and maintaining regulatory approvals and market confidence. In essence, Novavax's departmental structure is heavily weighted towards R&D, manufacturing, and regulatory affairs, characteristic of a company deeply involved in the full lifecycle of vaccine development and commercialization.
novavax's employees by locations
Employee Count by Country
Total: 940 employees
Novavax exhibits a global workforce distribution primarily anchored in the United States, reflecting its headquarters and core operational infrastructure. The concentration of employees in the United States (716 employees) indicates that the majority of R&D, manufacturing, and management functions are based domestically. A significant presence in Sweden (113 employees) and Czechia (70 employees) likely signifies strategic manufacturing partnerships, specialized R&D facilities, or access to skilled labor within the European Union to address European market needs. Switzerland's (13 employees) presence is indicative of operations necessary for commercial distribution in the country or strategic partnerships. The smaller presence in other European countries like the United Kingdom, Germany, Spain, Italy, Belgium, Ireland, and Austria suggests localized commercial or regulatory teams focusing on market access and government relations in those regions. Novavax's footprint in emerging markets, including Canada, Colombia, Malaysia, Philippines, Taiwan, Singapore, and South Korea, likely supports clinical trials, regulatory submissions, and market entry initiatives tailored to regional requirements. Overall, Novavax's geographic strategy balances a strong domestic base with a targeted international presence in Europe and strategic emerging markets to facilitate global clinical development, regulatory approvals, manufacturing diversification, and market access for its vaccine portfolio. The distribution strategy showcases an adaptable approach responding to evolving regulatory landscapes and clinical trial needs worldwide.
Want to stay ahead of novavax's org changes?
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early